Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
Under what circumstances would you use pasireotide in the management of insulinoma-associated hypoglycemia?
Vega-Beyhart, et al., PMID 40165498
Related Questions
Under what circumstances would you prioritize injectable semaglutide over oral semaglutide in patients with type 2 diabetes with atherosclerotic cardiovascular disease or chronic kidney disease?
What patients with new onset diabetes require imaging of the pancreas?
Would you recommend the 1-hour OGTT over the 2-hour OGTT for postpartum glucose tolerance testing in women with previous gestational diabetes?
What insulin pump features and settings do you utilize in patients with diabetes and end stage renal disease on intermittent hemodialysis or home peritoneal dialysis?
In patients using a tandem insulin pump on auto-mode/Control-IQ, would decreasing the basal settings on the profile actually reduce the delivered hourly insulin dose or is that only relevant if they switch to manual mode?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
How should clinicians balance the use of finerenone with other heart failure treatments like SGLT2 inhibitors, considering their glycemic benefits?
How do you recommend adjusting insulin pump settings when transitioning from U-100 to U-200 Humalog insulin?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
